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The role of the immune system in cancer is well
established. Indeed, most potential cancer causing
cells are detected and removed from our bodies by our
immune system in a process called “immune surveillance”.
However, at some point, tumors manage to evade our
immune system often by expressing signals that inhibit
the anti-tumor immune response (1). “The scientific
turning point for cancer immunotherapy came with
the understanding that T cell immune responses are
controlled through on and off switches, so-called ‘immune
checkpoints’ that protect the body from possibly damaging
immune responses” (2). Blockade of these checkpoints has
emerged as a new paradigm for the treatment of a cancer,
including NSCLC (3).
One of the most exciting therapeutic developments
currently in NSCLC involves targeting the checkpoint
involving the PD-1 [programmed death 1 (PD-1) receptor]
protein and its ligand, programmed death ligand 1 (PD-L1).
Monoclonal antibodies to either PD-1 or PD-L1 have
shown impressive response rates in NSCLC patients, and
have recently received regulatory approval to treat NSCLC
in both the EU and US (4,5).
Testing for expression of these checkpoint inhibitor
targets has proceeded apace with either companion
assays or complementary assays. A companion assay is a
necessary requirement for use of the corresponding drug,
whilst complementary assays are recommended in order
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to optimize appropriate patient selection, but are not
mandatory (6).
A positive PD-L1 IHC test has been shown to be
predictive of better responses and in many cases better
patient outcome for anti-PD1 and anti-PD-L1 based
therapies (7). In October 2015, a PD-L1 IHC test was
approved by the FDA as a companion diagnostic for
Pembrolizumab in treating advanced NSCLC (PD-L1 IHC
22C3 pharmDx™) (8).
However, accurate measurement and scoring of PDL1 protein expression are plagued by various technical and
biological pitfalls (7,9,10). Given the projected economic
costs for checkpoint inhibitors in NSCLC are of the order
of $130,511 for Pembrolizumab (11), this poses significant
challenges for hospital laboratories and pathologists,
only one of which is the issue of intra- and inter-observer
reproducibility of scoring for such companion diagnostics.
In an article to be published in Clinical Cancer Research
(In Press), Cooper and colleagues (12), assessed the FDA
approved PD-L1 companion diagnostic (PD-L1 IHC 22C3
pharmDx™). Ten pathologists examined two NSCLC
samples comprising two sample sets for the two established
cut-points for positivity (1% and 50%, with n=60 samples
for each) for both inter- and intra- observer reproducibility,
and further tested whether a one-hour training session could
affect assessment. Scoring for this study was only based
on a “tumor proportion score (TPS)”. Following analysis,
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for the 1% cut-off sample set the authors found that intraobserver reproducibility had an overall percent agreement
of 89.7% (95% CI: 85.7–92.6), whilst that for the 50% cutoff was 91.3% (95% CI: 87.6–94.0). For inter-observer
reproducibility the values for overall percent agreement at
the 1% cut-off were 84.2% (95% CI: 82.8–85.5), and at 50%
were 81.9% (95% CI: 80.4–83.3) (12). When compared
against a “gold standard” PD-L1 TPS, the concordance for
the 1% sample set was 84.3% for sensitivity (95% CI: 80.2–
88.5) and 91.3% for specificity (95% CI: 88.2–94.5). For the
50% sample set the concordance for sensitivity was 56.3%
(95% CI: 50.7–62.0) and specificity was 94% (95% CI: 91.3–
96.7). Surprisingly, the impact of a 1-hour training session
taken prior to a second assessment of the samples was found
to have no impact on overall percent agreements for the 1%
cut-off sample set, and only slight improvement for the 50%
cut-off set (rising from 78.3% to 81.7 %). When training
was assessed against the gold standard, minimal effects were
observed (1–87.3% as opposed to 87.7% pre versus post
training; 50–75.3% versus 78.7%) (12).
How does this compare against other studies?
The results from the various clinical trials of
Pembrolizumab have suggested that sensitivity of the 22c3
assay is 76% and the specificity is 60% (6). Most recently,
Rimm and colleagues also examined the PD-L1 IHC 22C3
pharmDx™ assay as part of a multi-institutional, pathologist
assessment of four of the current IHC assays for PD-L1
expression in a cohort of n=90 NSCLC specimens (13).
In this study 13 pathologists also scored sections according
to TPS. The concordance between pathologist’s scores
for tumor cells for the 22c3 assay was 0.822 (95% CI:
0.873–0.891). To estimate sensitivity, the authors “defined
the median pathologist’s score as “truth” and calculated
the correctly predicted proportion of positive cases as an
analogue for sensitivity and a correctly predicted proportion
negative as an analogue for specificity” (13). By this method
they found that the assay had 90% to 95% sensitivity
for either the 1% or 50% cut-off. When specificity was
examined the 1% cut-off had 70-80% specificity, while the
50% cut-off had greater than 95% specificity (13). Another
attempt to compare different PD-L1 IHC is the Blueprint
project (14). In this study this study three pathologists
assessed TPS in (n=39) NSCLC cases and used the 1% cutoff for analysis of concordance. In this regard, the 22c3
assay achieved 100% concordance (14).
There are limitations to all of the studies described
above, which necessitates caution with respect to direct
comparisons between these studies. For example, the
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Blueprint study and the study by Rimm and colleagues
were attempts to address the issue of concordance between
four separate PD-L1 assays (13,14), whereas in contrast
the study by Cooper and colleagues had a specific focus
on one particular assay. In addition it must be noted that
the Blueprint study as published was considered to be
a feasibility study, and was therefore not powered for
statistical analysis.
One study used exclusively full-face sections from
surgically resected cancers (13), one used a mixture of fullface sections and biopsy material (14), whilst the remaining
study utilized a tissue microarray (12). One well established
tenet of PD-L1 staining is that both inter- and intratumoral heterogeneity of staining is common (9). In this
regard, the number of replicate cores per patient in the
TMA used by Cooper et al., is not stated, and if only one
core per patient was used may have added a bias to the
analysis (12). Indeed assessment of cores rather than full
face sections may represent a relatively ‘easier task’ for the
participating pathologists given the smaller area of tumor
needed to derive the denominator of the TPS.
One issue between the study of Cooper et al. (12), and
Rimm et al. (13), was that the intra-assay variation between
pathologists for the percentage of tumor staining was better
for the 50% cut-point versus the 1% cut-point in Rimm
et al. (13,15), whilst in the study by Cooper and colleagues,
pathologists mostly underscored the samples in the 50%
cut-point range (12).
Another limitation to making direct comparisons
between these two studies potentially relates to the
statistical methodology used. Cooper et al., used Cohen’s
kappa coefficient, whilst due to the nature of the analysis/
cross comparisons Rimm et al., used the Fleiss kappa coefficient and Kendall’s concordance coefficient (12,13).
In the initial development of the PD-L1 IHC 22C3
pharmDx™ assay, the in-house analytical validation
comprising of inter-instrument, inter-operator, inter-day,
inter-lot, intra-day and intra-run variations found overall
percent agreement was 100%. When reproducibility was
tested at different external laboratories, the concordance
was slightly lower with an overall percent agreement of
88.8% (8). The results from the three additional studies
appear to support these initial observations appear to
indicate that the PD-L1 IHC 22C3 pharmDx™ assay is
robust with good reproducibility at both 1% and 50% cutpoints. However, it must be noted that all of the pathologists
taking part in these studies have significant experience in
scoring IHC biomarkers. In effect, once the pathologists
“eye” is trained in, the concordance and reliability of assays
such as the PD-L1 IHC 22C3 pharmDx™ assay are robust.
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Therefore, should all assays for PD-L1 testing be conducted
by experienced personnel, or should there be centralized
testing for patients for suitability for Pembrolizumab
treatment? Finally, the question still remains, what to do
for the approximately 15% of patients, classified as PD-L1
negative by IHC, that actually respond to therapy? (7).
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